Bio Aurum, saffron against neurodegenerative disorders
Bio Aurum will become a key player in the booming sector of nutraceuticals due to the solid expertise of CSO and to ownership of a patent for a product ready to market with similar characteristics to the one proposed.
The CSO and R&D team have more than a decade in basic research in the field of neurodegenerative disorders and exploit the curative properties of a trademark protected active ingredient derived from endemic saffron with scientifically proven therapeutic properties.
The solutions proposed by Bio Aurum target Alzheimer’s disease and degenerative maculopathy with particularly focus on Stargardt’s disease.
The first proposed product has terminated preclinical studies and is ready to be tested on humans while the second is ready to market.
The novel IPR protected technology and related products permit the employment of naturally occurring bioactive molecules that target multiple pathogenic steps of neurodegenerative and degenerative diseases without the side effects of current standard available therapies that often have to be combined. National health structure is available for the recruitment of patients and the development of phase I clinical trials.
The most common form of dementia in the elderly is Alzheimer‘s disease which causes progressive memory loss, mental function disorders, apathy, and disorientation. At present, treatments to prevent the development or progression of Alzheimer‘s and to alleviate some of the symptoms generally show modest and temporary efficacy.
In recent decades, several studies have shown the existence of a large number of potentially mutable risk factors for the development of dementia, therefore able to constitute objectives for prevention strategies.
In particular, the association between eating habits and cognitive performance is becoming increasingly evident.
Recent meta-analysis studies indicate that different dietary patterns and nutritional components (e.g. Mediterranean diet and elements with documented antioxidant activity) are associated with a significantly reduced risk of developing dementia.
The therapeutic strategies now available are not resolutive, as they do not slow down the progression of the disease but are limited to symptomatic treatment.
A correct diet and the intake of natural substances containing the macromolecules necessary for the physiological processes of our body can help us in the prevention of diseases and in the management of symptoms. Since ancient times, in fact, it is renowned that a diet rich in antioxidants protects from degenerative diseases in the elderly and recent scientific studies correlate a balanced diet, rich in antioxidants, with the prevention of Alzheimer’s disease.
Following decades of research on saffron’s neuroprotective effects in macular degeneration and retinitis pigmentosa, it was employed in a pilot study on patients with Stargardt disease/fundus flavimaculatus (STG/FF).
Stargardt’s disease is the most common hereditary macular dystrophy. Prevalence is estimated between 1 in 8,000 and 1 in 10,000. Disease onset occurs typically in the first or second decade of life and manifests as decreased visual acuity. This disease has usually an autosomal recessive inheritance pattern. It has been associated with mutations in the ABCR gene, which encodes a transmembrane transporter protein expressed by the rod outer segments. There is currently no treatment available for Stargardt’s disease.
The study conducted by Bioaurum’s CSO was a randomized, double-blind, placebo-controlled study employing 31 patients with ABCA4-related STG/FF and a visual acuity >0.25 and lasted six month period and then reverted to placebo or therapy for a further six month period. The results showed that six months of saffron supplementation was well tolerated and had no detrimental effects on the electroretinographic responses of the central retina. The findings also suggest that saffron supplementation may prevent progressive deterioration of macular fERG amplitude, as observed in patients assigned first to placebo and then to saffron treatment.
Long-term follow-up of 36 months was obtained outside the period of the clinical trial in a subgroup of our patients. The obtained data suggest a long-term safety of supplementation and possible visual stabilization.
TARGET MARKET: The company, through its technologies targets the following markets:
- The neuro-degenerative pathologies market: this market shows a TAM of 27.0b USD and projects a CAGR of 7.5% on average until 2023
Saffron is proposed as an alternative phytotherapeutic resource to synthetic pharmacology.
The merit of Bio Aurum lines in having brought a pure, 100% natural nutraceutical to the health care market. The use of natural antioxidants is a biocompatible and cost-effective alternative to synthetic antioxidants. Bio Aurum’s innovation is based on 100% natural products without the addition of additives or synthetic molecules.
The ancient Red Gold holds, in fact, several beneficial properties in itself, including anti-aggregating function:
- It slows down or prevents the oxidation of cells and increases the availability of oxygen in our body;
- Counteracts aging: since saffron is one of the most powerful antioxidants, it counteracts free radicals, responsible for accelerating cellular aging;
- It favors the digestive functions: it stimulates the digestive system, increasing the secretion of bile and gastric juices;
- Reduces the deposit of lipofuscin, the waste that cells accumulate with aging;
- Leaves no metabolites (residues) in the organs and has no side effects.
Alzheimer’s disease is a major source of morbidity with the disease burden expected to rise as the population ages. No disease-modifying agent is currently available.
Literature and ongoing research suggest that nutritional and lifestyle modifications can delay or prevent the onset of Alzheimer’s disease (1). Neurodegenerative diseases are often triggered by oxidative and nitrosative stress and sustained by inflammatory cytokine production (2).
Bio Aurum solution exhibit in vitro and in vivo antioxidant and anti-inflammatory properties, acting at a cellular level on various depicted metabolic pathways.
Bio Aurum, from the processing of saffron, has obtained Zoìkos: a product with beneficial and therapeutic properties that effectively fight the evolution of neurodegenerative diseases, especially Alzheimer’s.
ZoìKos (from Greek: “home of life”) is a unique product: it is pills made of a 100% natural substance, which have a therapeutic action that can prevent the effects of Alzheimer‘s and other neurodegenerative diseases, drastically slowing down the progression.
The product is produced in an eco-sustainable way from endemic raw materials of the best quality.
Saffron acts on various metabolic pathways, acting when the cell begins to lose its usual functions. The therapeutic effect, in fact, comes to life when the degenerative process begins, immediately slowing down the progression of the disease.